Investigational drug · Phase 3
Copper Cu 64 PSMA I&T
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Prostate Cancer, Prostate Adenocarcinoma, Biochemical Recurrence of Malignant Neoplasm of Prostate.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "Copper Cu 64 PSMA I&T"
First trial start
2024
Apr 1, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Copper Cu 64 PSMA I&T", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prostate Cancer
- Prostate Adenocarcinoma
- Biochemical Recurrence of Malignant Neoplasm of Prostate
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Copper Cu 64 PSMA I&T" as an intervention, largest first.
- Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate CancerPivotal-lookingCompleted
Curium US LLCIndustry
NCT06235151 · 443 participants · Start Apr 1, 2024 · Primary completion Oct 30, 2026
Drug: Copper Cu 64 PSMA I&T · For: Prostate Cancer; Prostate Adenocarcinoma
Sites: Homewood, Alabama; Little Rock, Arkansas; Fullerton, California · 43 sites in all
- Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate CancerPivotal-lookingCompleted
Curium US LLCIndustry
NCT06235099 · 235 participants · Start Apr 1, 2024 · Primary completion Feb 18, 2025
Drug: Copper Cu 64 PSMA I&T · For: Prostate Cancer; Prostate Adenocarcinoma; Biochemical Recurrence of Malignant Neoplasm of Prostate
Sites: Fullerton, California; Los Angeles, California; Newport Beach, California · 31 sites in all
Curium US LLCIndustry
NCT05653856 · 26 participants · Start Dec 5, 2022 · Primary completion May 17, 2023
Drug: 64Cu-PSMA I&T · For: Metastasis From Malignant Tumor of Prostate (Disorder)
Sites: New Haven, Connecticut; Hines, Illinois; Baltimore, Maryland · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Prostate Cancer
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
- aglatimagene besadenovecCAN-2409, AdV-tkPhase 35 trials
Candel Therapeutics, Inc. · Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
- 64Cu-SAR-bisPSMAPhase 33 trials
Clarity Pharmaceuticals Ltd · Prostate Cancer, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms
- Leuprorelin acetateLeuprolide Open Label, DKF-MA102Phase 33 trials
Pfizer · Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
- MevrometostatPF-06821497Phase 33 trials
Pfizer · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.